The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.
- Published In:
- Expert opinion on investigational drugs, 34(3), 197-215 (2025)
- Authors:
- Madsbad, Sten(9), Holst, Jens J(18)
- Database ID:
- RPEP-12388
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12388APA
Madsbad, Sten; Holst, Jens J. (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.. Expert opinion on investigational drugs, 34(3), 197-215. https://doi.org/10.1080/13543784.2025.2472408
MLA
Madsbad, Sten, et al. "The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.." Expert opinion on investigational drugs, 2025. https://doi.org/10.1080/13543784.2025.2472408
RethinkPeptides
RethinkPeptides Research Database. "The promise of glucagon-like peptide 1 receptor agonists (GL..." RPEP-12388. Retrieved from https://rethinkpeptides.com/research/madsbad-2025-the-promise-of-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.